The Role of Everolimus in Renal Cell Carcinoma

Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell renal ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Meskawi, Malek, Valdivieso, Roger, Dell’Oglio, Paolo, Trudeau, Vincent, Larcher, Alessandro, Karakiewicz, Pierre I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345521/
https://www.ncbi.nlm.nih.gov/pubmed/28326273
http://dx.doi.org/10.15586/jkcvhl.2015.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345521/
https://www.ncbi.nlm.nih.gov/pubmed/28326273
http://dx.doi.org/10.15586/jkcvhl.2015.43

Ejemplares similares